Answers are grounded in this paper and cite their sources.
This approval, the first for any regimen for the neoadjuvant treatment of NSCLC in the United States, was supported by a statistically significant and clinically meaningful improvement in EFS with no evidence of detriment in OS or negative impact on patients' receipt and timing of surgery or surgical outcomes.
No takes yet. Share an insight, caveat, or question.
Akinboro et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: